Akshat Jain/Photo:
lluh.org
Apr 22, 2026, 07:40
Akshat Jain: WIL33 Study Advances Factor Prophylaxis in Children with von Willebrand Disease
Akshat Jain, Hematology Pediatric Workforce Task Force at American Society of Hematology, shared a post on LinkedIn:
”It was wonderful presenting our research on factor prophylaxis for Children with Von Willebrand Disease at the WFH 2026 congress.
How we treat VWD especially in young children remain undetermined in the absence of robust clinical trials and medications that always are late to arrive for pediatric indications.
Through the WIL33 study (7 country, 3 continents ) that I had the honor to lead for Octapharma this gap has been addressed and real world care can start to be defined to assist clinicians world over.”
Stay updated with Hemostasis Today.
-
Jun 24, 2026, 03:36Ana Pedrero Gil: A New Approach to Post-Tonsillectomy Hemorrhage
-
Jun 24, 2026, 02:59Melissa Hollo: Making Early Anemia Detection the Standard of Care
-
Jun 24, 2026, 02:51Bruno Pougault: The Thin Line Between Bleeding and Clotting
-
Jun 23, 2026, 23:30Shunsuke Iwano: PMDA Introduces Greater Flexibility for Pediatric Factor VIII and IX Development in Japan
-
Jun 23, 2026, 23:05Rounak Dubey: ISBT Academy Session on Agentic AI
-
Jun 23, 2026, 22:59Mohammed Maher Babiker: When ‘Low Platelets’ aren’t Really Low
-
Jun 23, 2026, 22:49Giovanni Merlino: Why Does Stress Hyperglycemia Worsen Stroke Outcomes?
-
Jun 23, 2026, 22:41Tareq Abadl: Coombs Test – The Key to Detecting Immune-Mediated Hemolysis
-
Jun 23, 2026, 22:32How WFH Impacted the Bleeding Disorders Community in 2025